Authors : Mohammed S. Abdelaziz, Hagir E. Mohagir, Ali Yousif Babiker, Mohamed A. Alsahli, Saleh A. Almatroodi and Arshad H. Rahmani
Abstract: The aim of study was to evaluate the expression pattern of Alpha-methylacyl-CoA Racemase (AMACR) in prostate tumors. In order to examine the relationship between AMCAR expression and tumor, we analyzed a total of 10 cases of benign prostatic hyperplasia and 20 cases of prostate adenocarcinoma . Expressions pattern of AMCAR were analysed and found that only one case (10%) of benign prostatic hyperplasia showed expression whereas 19 cases (95%) of prostate adenocarcinoma showed expression at different levels of intensity. The difference in expression pattern among benign prostatic hyperplasia and prostate adenocarcinoma was statically significant (p>0.05). Expression profile were further categorised according to grade of the tumor and found that AMCAR was expressed in 4 (100%), 6 (100%) and 9 (90%) in well, moderate and poor differentiated prostate adenocarcinoma respectively. This difference of expression among the different types of grade was statistically insignificant (p>0.05). Our results concluded that AMCAR is a valuable diagnostic and prognostic marker of prostate cancer and one of the vital factors in pathogenesis of prostrate adenocarcinoma.
Mohammed S. Abdelaziz, Hagir E. Mohagir, Ali Yousif Babiker, Mohamed A. Alsahli, Saleh A. Almatroodi and Arshad H. Rahmani, 2016. Immunohistochemical Detection of Alpha-Methyl-Co-Racemase (AMACR) in Adenocarcinoma of Prostate. Research Journal of Medical Sciences, 10: 707-710.